Meeting
2023 ASCO Breakthrough
Effect of exercise mode specificity on quality of life in prostate cancer patients undergoing androgen suppression.
Authors
Dennis R Taaffe
Exercise Medicine Research Institute, Edith Cowan University, Joondalup, Australia
Dennis R Taaffe , Robert Usher Newton , Nigel Spry , Suzanne K Chambers , Robert Alexander Gardiner , Pedro Lopez , David John Joseph , Daniel Abido Galvao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Local Disease
Clinical Trial Registration Number
ACTRN12609000200280
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 72)
DOI
10.1200/GO.2023.9.Supplement_1.72
Abstract #
72
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer.
First Author: Tanya B. Dorff
Poster
2024 ASCO Genitourinary Cancers Symposium
Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life.
First Author: Sagar A. Patel
Poster
2023 ASCO Annual Meeting
Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).
First Author: Daniel Sentana Lledo
Poster
2023 ASCO Annual Meeting
Exercise to enhance cardiovascular health among Black patients with prostate cancer with androgen deprivation therapy: The POWER trial.
First Author: Dong-Woo Kang